GDC-0339

• UNSPSC Description:

  GDC-0339 is a potent, orally bioavailable and well tolerated pan-Pim kinase inhibitor, with Kis of 0.03 nM, 0.1 nM and 0.02 nM for Pim1, Pim2 and Pim3, respectively. GDC-0339 is discovered as a potential treatment of multiple myeloma[1][2].

• Target Antigen:

  Pim

• Type:

  Reference compound

• Related Pathways:

  JAK/STAT Signaling

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/GDC-0339.html

• Solubility:

  DMSO : ≥ 52 mg/mL

• Smiles:

  FC1=CC=CC(F)=C1C2=NC(C(NC3=C(N4CC[C@@H](F)[C@H](N)CC4)N(C)N=C3)=O)=C(N)S2

• Molecular Weight:

  465.50

• References & Citations:

  [1]Takahashi RH, et al. CYP1A1-Mediated Intramolecular Rearrangement of Aminoazepane in GDC-0339. Drug Metab Dispos. 2017 Oct;45(10):1084-1092.|[2]Wang X, et al. Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple Myeloma. J Med Chem. 2019 Feb 28;62(4):2140-2153.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1428569-85-0